Relapsed or refractory pediatric patients with B-acute lymphoblastic leukemia (B-ALL) have high rates of toxicities and relapse, and novel therapy is needed. We present a case of a 5-year-old male child with high-risk B-ALL that was refractory to several re-induction regimens. He was put into minimal residual disease-negative remission after re-induction with chemotherapy plus overlapping rituximab, inotuzumab ozogamicin, and blinatumomab, termed mini-hyper-CVD (cyclophosphamide, vincristine, and dexamethasone) plus CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab). This regimen was well tolerated, and he received his transplant and engrafted with no significant infections, toxicities, or sinusoidal obstruction syndrome. This is the first reported use of a condensed sequential immunotherapy/chemotherapy regimen in a pediatric leukemia patient.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.29939 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia.
Blood
September 2024
Mayo Clinic, Rochester, Minnesota, United States.
Although complete remission rates in adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have improved over the last two decades, it is still inferior to that of the pediatric population and once in remission, the risk of relapse is still high. Furthermore, while pediatric-inspired chemotherapy regimens have improved long-term outcomes for adolescents and young adults, these intensive chemotherapy regimens are not well tolerated in older patients and are associated with higher morbidity and mortality. Immunotherapeutic agents offer a potential opportunity to improve response and decrease relapse without increasing toxicity.
View Article and Find Full Text PDF[Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development].
Gan To Kagaku Ryoho
July 2024
Dept. of Hematology and Oncology, University of Fukui.
Article Synopsis
- * In Japan, four ADCs are approved: gemtuzumab ozogamicin for acute myeloid leukemia, brentuximab vedotin for various types of Hodgkin's and T-cell lymphomas (showing improved progression-free survival), inotuzumab ozogamicin for B-cell acute lymphoblastic leukemia (with higher remission rates), and polatuzumab vedotin for diffuse large B-cell lymphoma (which also improves outcomes when used with standard chemotherapy).
- * Despite their
Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL).
Curr Treat Options Oncol
September 2024
Women and Child Health Department, Taibah University, Madinah, Kingdom of Saudi Arabia.
Acute lymphoblastic leukemia (ALL) represents the predominant cancer in pediatric populations, though its occurrence in adults is relatively rare. Pre-treatment risk stratification is crucial for predicting prognosis. Important factors for assessment include patient age, white blood cell (WBC) count at diagnosis, extramedullary involvement, immunophenotype, and cytogenetic aberrations.
View Article and Find Full Text PDFLow-dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe-BIRD) in a child with relapsed/refractory B-cell acute lymphoblastic leukemia with TP53 mutation.
Pediatr Blood Cancer
September 2024
Department of Hematology and Bone Marrow Transplant, Paras Health, Gurugram, Haryana, India.
Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Haematologica
September 2024
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!